Related Experiment Video

Updated: Jul 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Androgen receptor and growth factor signaling cross-talk in prostate cancer cells

Meng-Lei Zhu1, Natasha Kyprianou

  • 1Departments of Urology and Toxicology, University of Kentucky College of Medicine, University of Kentucky Medical Center, Combs Research Building Room 306, Lexington, Kentucky 40536, USA.

Endocrine-Related Cancer
|August 1, 2008
PubMed

Insights

Androgen receptor (AR) signaling interacts with growth factors, driving prostate cancer growth. Targeting this cross-talk offers a new strategy for treating androgen-independent prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Androgens regulate prostate cell growth via the androgen receptor (AR).
  • Growth factor signaling pathways can sensitize the androgenic response.
  • This sensitization contributes to the development of androgen-independent prostate tumors.

Purpose of the Study:

  • To review the functional interactions between the androgen receptor (AR) and growth factor signaling pathways in prostate tumors.
  • To discuss the significance of this cross-talk in prostate cancer progression.
  • To explore therapeutic strategies targeting this interaction in metastatic prostate cancer.

Main Methods:

  • Literature review of studies on AR and growth factor signaling in prostate cancer.
  • Analysis of the cross-talk mechanisms between AR and growth factor pathways (EGF, FGF, IGF1, VEGF, TGF-β).
  • Discussion of the implications for prostate cancer progression and treatment.

Main Results:

  • AR cross-talks with key growth factor signaling pathways to regulate cell cycle, apoptosis, and differentiation.
  • Derailed cross-talk contributes to prostate cancer progression and the emergence of resistance.
  • Specific growth factors reviewed include EGF, FGF, IGF1, VEGF, and TGF-β.

Conclusions:

  • The interaction between AR and growth factor signaling is crucial in prostate cancer.
  • Dysregulated cross-talk promotes tumor progression and therapeutic resistance.
  • Targeting these signaling networks presents a promising therapeutic avenue for advanced prostate cancer.

More Related Videos

RhoC GTPase Activation Assay09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...